Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly and Company ("Lilly") to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs.

Profluent will receive an upfront payment in addition to committed research and development funding. In total, Profluent is eligible to receive up to $2.25 billion in development and commercial milestone payments plus tiered royalties on net sales. Further details of the agreement have not been disclosed.